Image courtesy of Pexels.

Traveling abroad without the right protections is not only a risk for the traveler, but also for the people around them. Recently, an adult without measles protection flew from Europe to the United States while infected with the virus. They ultimately spread measles to 17 other people.

These findings come from the U.S. Centers for Disease Control and Prevention (CDC) and were published in the Journal of Infectious Diseases.

How Did Researchers Investigate the Outbreak?

The report drew case information from the CDC’s Port Health Activity reporting system. Researchers also reviewed state and local health department investigations involving contact tracing, community transmission, and laboratory testing.

Additionally, they analyzed flight records to determine where exposures and infections most likely occurred.

The CDC received notification in May 2025 that an adult had flown from Europe to Denver International Airport in Colorado. After spending the night at a hotel, the traveler boarded a domestic flight and returned home to North Dakota.

During the trip, the infected traveler developed fever, cough, pink eye, and other symptoms. One day after arriving home, they showed the characteristic measles rash.

How Many People Became Infected?

Through contact tracing, researchers identified 135 travelers who had been exposed. Fifteen of those individuals became infected with measles.

The infected group included 13 adults and two children. Five infections occurred during the international flight, three during the domestic flight, and seven were linked to exposure at the airport.

The outbreak did not stop there. Two additional people were infected through contact with individuals exposed during the travel-related outbreak, bringing the total to 17 cases.

Of the 15 people infected directly by the traveler, 10 had received at least one dose of a measles vaccine, while five were unvaccinated. Five people required hospitalization, including three vaccinated individuals and two unvaccinated individuals. Among the two secondary cases, one involved transmission from a vaccinated person to another vaccinated person. The other occurred between two unvaccinated adults.

Why Is Measles Vaccination Important Before Travel?

The study authors emphasized that measles vaccination before international travel is critical for everyone aged 6 months and older who is eligible for vaccination.

They also urged anyone experiencing symptoms such as fever, cough, or other signs of illness to reconsider or postpone travel to reduce the risk of spreading infection.

International travel can expose people to diseases that are uncommon at home. Staying up to date on recommended vaccines and avoiding travel when sick can help protect both travelers and the communities they visit.

Before your next trip, speak with a travel health specialist about recommended vaccinations and other preventive measures.

Conclusion

An unvaccinated traveler spread measles throughout the United States last year. Vaccination remains the best protection for travelers and communities alike. Postponing travel while sick helps prevent future outbreaks and hospitalizations.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

Few statistics are more troubling than childhood mortality. Around the world, roughly 5 million children die each year. Even more concerning, many of these deaths are preventable.

Recently, Our World in Data released a tool that breaks down global childhood mortality data from 2023. The findings, collected from a recent report, reveal that infectious diseases remain a major threat to children, especially in lower-income countries.

What Are the Findings?

Globally, respiratory infections accounted for 14% of childhood deaths. This category includes illnesses such as pneumonia, influenza, COVID-19, and other respiratory diseases. On an average day in 2023, nearly 2,000 children died from respiratory infections.

Malaria was the second-largest disease-related cause of childhood mortality, accounting for nearly 9% of deaths. Diarrheal illnesses, including rotavirus, cholera, and other infections, made up almost 7%. Another 4% of deaths resulted from other infectious diseases, while measles caused approximately 2.5%.

These findings show that infectious diseases are nearly as significant a cause of childhood death as birth-related complications. Birth disorders are largely driven by preterm birth and neonatal suffocation. Together, infectious diseases and birth-related conditions each account for more than 40% of global childhood mortality.

However, global statistics can hide major differences between countries. The data highlight a stark contrast between Nigeria and the United Kingdom. A child born in Nigeria faces more than 20 times the risk of dying before age five compared with a child born in the UK.

In Nigeria, infectious diseases accounted for 56% of childhood deaths. Malaria was the single deadliest disease. This is especially tragic because malaria is largely preventable through measures such as mosquito control, preventive medicines, and timely treatment.

Respiratory infections accounted for another 15% of childhood deaths in Nigeria. Diarrheal diseases caused 8.5%, while other infectious diseases contributed 5.6%.

Many of these illnesses can be prevented through vaccination and basic public health measures. Yet access to preventive healthcare remains limited. Only about 57% of Nigerian children receive the rotavirus vaccine. Vaccination rates are even lower for some other diseases. Roughly one-third of children receive a measles vaccine, and coverage remains similarly low for meningitis and whooping cough vaccines.

The picture looks very different in wealthier countries. In the UK and other developed nations, childhood deaths are much less likely to result from infectious disease. Instead, birth complications and non-communicable conditions account for a larger share of mortality.

According to the UK data, only 2.7% of childhood deaths were linked to respiratory infections. Nearly 40% resulted from preterm birth. Advances in medicine, vaccination, sanitation, and healthcare access have dramatically reduced the burden of many infectious diseases.

Older children face a somewhat different pattern of risk. Among children ages 5 to 14, infectious diseases remain a significant cause of death worldwide.

Nineteen percent of deaths in this age group resulted from infectious diseases other than respiratory illnesses. Respiratory infections accounted for another 10%. Diarrheal diseases and malaria each caused 5.2% of deaths, while tuberculosis was responsible for 2.1%.

Although mortality rates are lower among older children than among infants, these numbers still represent a substantial burden of preventable disease.

What’s Next?

Overall, the data demonstrate how many young lives could be saved through relatively low-cost interventions. Vaccines, improved sanitation, mosquito-control programs, and access to basic healthcare already exist. The challenge is ensuring that these tools reach the children who need them most.

When millions of children continue to die from preventable diseases, the problem is not simply medical. It is also a question of priorities. Expanding access to preventive healthcare could save countless lives and spare families around the world from needless loss.

Conclusion

Childhood mortality remains a major global health challenge, with millions of deaths linked to preventable infections each year. Differences between countries show how access to vaccines, healthcare, and public health measures can improve survival. Expanding these low-cost interventions could save countless children from needless death.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of NIAID.

Sometimes, the solution to a problem is simpler than it first appears. The real barrier may not be the difficulty of the issue itself, but failing to recognize an obvious answer. People often step away, take a short walk, or sleep on a problem. After a reset, what once seemed complex can suddenly feel clear and manageable.

Recent research suggests a similar kind of breakthrough in medicine. Scientists have identified an unexpected but straightforward weapon against one of the most dangerous antibiotic-resistant bacteria. A common blood pressure medication can fight methicillin-resistant Staphylococcus aureus, better known as MRSA.

What is MRSA?

MRSA is a form of staph bacteria that has adapted to survive many common antibiotics. Antibiotic resistance is one of the most serious health threats in the world today. In the United States alone, resistant infections cause nearly 3 million illnesses and more than 35,000 deaths each year. MRSA remains a major part of that crisis.

The bacteria were once thought to spread mainly in hospitals and healthcare settings. However, MRSA now appears in schools, gyms, homes, and other community spaces as well. It can cause skin infections, pneumonia, and life-threatening bloodstream infections.

One reason MRSA is so difficult to treat is its ability to form biofilms. Biofilms are slimy protective layers that help bacteria attach to surfaces. These barriers also shield bacteria from immune attacks and many drug treatments. That makes infections harder to eliminate and raises the risk of repeat infections.

What Are the Findings?

Instead of trying to invent an entirely new antibiotic, researchers explored whether an existing medication could be repurposed. Their focus was the bacterial cell membrane, the outer surface that controls what enters and exits the cell.

They found that candesartan cilexetil, a widely used blood pressure medication, showed a strong ability to damage MRSA cell membranes. This was a surprising discovery because the drug was originally designed for heart and blood pressure care, not bacterial infections.

The researchers reported that candesartan cilexetil disrupted MRSA cells at multiple stages of development. It also interfered with other important cell functions. Just as importantly, the medication helped prevent biofilms from forming in the first place.

That combination could make MRSA far easier to treat. Without an intact membrane or protective biofilm, the bacteria become more exposed, weaker, and less able to spread.

There is another major advantage to this approach. Candesartan cilexetil is already an approved medication. As such, the path toward testing for new uses may be faster and less expensive than developing a brand-new antibiotic from scratch.

Much more research is still needed before this drug could become a standard MRSA treatment. Scientists must confirm safety, dosage, and effectiveness in human trials. Still, the findings offer hope at a time when antibiotic resistance continues to grow.

Sometimes the best answer is not hidden in something new. Sometimes it is waiting in plain sight.

Conclusion

Researchers found that a common blood pressure drug may help kill dangerous MRSA bacteria. The medication damages bacterial defenses and may stop protective biofilms from forming. Because the drug already exists, it could reach future treatment use faster.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

Forests are often considered treasure troves for undiscovered medicines. New research suggests one Brazilian tree may contain compounds capable of fighting COVID-19. These findings highlight the medical potential of nature and the importance of protecting ecosystems.

The tree, Copaifera lucens Dwyer, grows in Brazil’s Atlantic Forest. Researchers discovered that compounds extracted from its leaves showed strong antiviral activity against SARS-CoV-2, the virus responsible for COVID-19. These compounds are called galloylquinic acids. Many antiviral drugs target only one viral process. Galloylquinic acids, meanwhile, attack the virus from multiple directions simultaneously.

Researchers found that these compounds blocked SARS-CoV-2 from entering human cells. They also interfered with the virus’s ability to reproduce itself after infection. In addition, the compounds reduced inflammation and appeared to improve immune system responses. This multi-targeted action makes the compounds especially promising as a potential antiviral.

What Are the Findings?

Many current antiviral drugs focus on a single viral mechanism. Viruses can sometimes mutate around these treatments, leading to antiviral resistance. Galloylquinic acids may lower this risk because they affect several viral systems at once. Researchers believe this broader approach could make it more difficult for the virus to adapt and survive.

Scientists focused on Copaifera lucens because they had already been studying the broader Copaifera genus. Previous research suggested these trees contained medically valuable compounds. Galloylquinic acids had already shown antifungal and anticancer properties in laboratory studies and animal models. Earlier studies also found antiviral effects against HIV-1, often with fewer harmful side effects.

Before testing antiviral activity, researchers first conducted cytotoxicity tests. These evaluations ensured the compounds were not dangerously harmful to healthy cells. Scientists then used plaque reduction assays to measure how effectively the compounds destroyed viral particles. The results showed strong activity against SARS-CoV-2.

The research team also studied how galloylquinic acids interacted with several important viral components. One target was the SARS-CoV-2 spike protein, which allows the virus to attach to and enter human cells. Researchers also examined PLpro, an enzyme helping the virus evade immune detection. Another target was RNA polymerase, which the virus uses to replicate itself.

Results showed the compounds strongly affected these viral systems. Galloylquinic acids reduced viral protein production, limited viral replication, and blocked cell infiltration. At the same time, they reduced harmful inflammation linked to severe COVID-19 infections.

What’s Next?

Researchers caution that much more work remains before treatments become available. Future studies must test these compounds in animals and eventually human trials.herapy intended to act within the central nervous system.

The findings also highlight the importance of environmental conservation. Brazil’s Atlantic Forest continues facing rapid deforestation and habitat destruction. Protecting ecosystems like these may preserve valuable natural compounds.

Conclusion

Researchers discovered natural compounds in a Brazilian tree that fight COVID-19. The compounds blocked viral entry, replication, and inflammation during laboratory testing. Scientists say protecting forests may preserve future medicines hidden within threatened ecosystems.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

Sometimes medications and vaccines reveal benefits far beyond their original purpose. Researchers recently linked GLP-1 medications to tissue regeneration in joints like the knees. Shingles vaccines may offer another surprising example. In addition to preventing painful shingles infections, growing evidence suggests they may also protect the brain and heart.

Researchers recently found that shingles vaccination may sharply reduce cardiovascular risks in older adults already living with heart disease. Their findings were presented during the annual scientific session of the American College of Cardiology in New Orleans.

What Are the Findings?

Heart disease remains one of the leading causes of death worldwide. Older adults face especially high risks for heart attacks, strokes, and heart failure. Researchers now believe shingles vaccination could help lower some of these dangers.

The study examined electronic health records from nearly 250,000 adults in the United States. All participants were at least 50 years old and had been diagnosed with heart disease between 2018 and 2025. Researchers gathered the information using TriNetX, a large health database containing records from millions of Americans.

About half of the participants had received at least one shingles vaccine dose. These vaccines included Shingrix or Zostavax. Researchers then matched them with a similarly sized unvaccinated control group.

The research team also studied how galloylquinic acids interacted with several important viral components. One target was the SARS-CoV-2 spike protein, which allows the virus to attach to and enter human cells. Researchers also examined PLpro, an enzyme helping the virus evade immune detection. Another target was RNA polymerase, which the virus uses to replicate itself.

From one month to one year after vaccination, the results appeared striking. Vaccinated participants showed a 40% lower risk of major adverse cardiovascular events. They also experienced a 66% lower risk of death from any cause during that timeframe.

The protective effects extended across several major conditions. Vaccinated individuals showed a 32% lower chance of heart attack. Stroke risk fell by roughly 22.5%. Heart failure risk also declined significantly.

Researchers noted that these improvements resemble the cardiovascular benefits seen after quitting smoking. Such findings suggest shingles vaccination may offer broader health protection than previously understood.

Scientists believe the connection may stem from how shingles affects blood vessels and inflammation. Shingles develops when the virus responsible for chickenpox reactivates later in life. The infection can trigger inflammation and clot formation around the brain, heart, and blood vessels.

Previous studies already linked shingles infections to elevated risks of heart attacks, strokes, and dangerous blood clots. By preventing shingles outbreaks, vaccines may stop many of these harmful inflammatory processes before they begin.

The findings also build upon earlier research connecting shingles vaccination to lower dementia risk. Some studies suggest vaccinated individuals may face reduced chances of developing dementia later in life. Researchers continue investigating how reduced inflammation and viral activity may influence long-term brain health.

The Centers for Disease Control and Prevention currently recommends shingles vaccination for adults aged 50 and older. Younger adults with weakened immune systems are also advised to receive the vaccine.

Researchers acknowledged several limitations within the new study. Because the analysis only followed participants for up to one year, longer-term effects remain uncertain. People who receive vaccines may also practice healthier lifestyles overall, potentially influencing outcomes.

Still, researchers adjusted for differences involving health conditions and socioeconomic factors. Combined with the study’s massive sample size and strong statistical methods, they remain confident that shingles vaccination is linked to lower cardiovascular risk in older adults with heart disease.

Conclusion

Shingles vaccines may protect more than nerves and skin. Researchers found vaccinated older adults with heart disease had sharply lower risks for heart attacks, strokes, heart failure, and death. Scientists believe preventing shingles infections may also prevent harmful inflammation and blood clots.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

Recently, more and more people have elected to board a plane and cross borders to get medical care, particularly for expensive procedures such as dental surgeries, experimental therapies, or cosmetic procedures. Many hope to avoid steep costs while still receiving the care they need. Researchers investigating medical tourism for cosmetic care found that these surgeries often carried health risks, particularly bacterial infections. Results were published in Emerging Infectious Diseases.

There is no exact figure on how many people travel abroad for cosmetic procedures. However, researchers said the practice is likely to increase. The prediction is understandable, considering rising living costs and difficulty accessing affordable medical care, including reliable insurance coverage.

Money is not the only motivation. Time also plays a major role. Patients who may otherwise face months- or years-long waits for surgery sometimes choose to travel overseas where procedures are available much sooner.

How Did Researchers Investigate Cosmetic Tourism?

To conduct the study, researchers analyzed written and verbal requests sent from health departments to the Centers for Disease Control and Prevention (CDC). They searched for cases involving people who traveled to another state or country for cosmetic surgery between January 2014 and December 2024.

The reported cosmetic procedures included liposuction, tummy tucks, Brazilian butt lifts, breast augmentation, and other surgeries. Researchers recorded cases where these procedures were associated with bacterial infections or other serious health concerns.

Across 21 reports representing 145 individual cases, traveling across state or national borders for cosmetic surgery was linked to negative health outcomes. Infection occurred in 20 of the 21 reports, with non-tuberculous mycobacteria identified in 12 patients. Four of the reports also sought CDC assistance following a patient’s death associated with one of the reported infection outbreaks.

Why Does Cosmetic Tourism Create Risks?

Open surgical wounds can provide bacteria with an opportunity to enter the body. When infections are acquired abroad, they can also be more difficult to detect, treat, and trace. This can delay diagnosis, complicate treatment, and increase the risk of additional infections or more severe illness.

Standards for infection prevention, equipment sterilization, and reporting practices may also vary between facilities and countries. In many cases, patients do not notify health authorities that they traveled for cosmetic surgery, and overseas clinics may not report infections to the patient’s home country. As a result, outbreaks become more difficult to identify and investigate.

It is important for healthcare providers to discuss the potential risks of medical tourism with patients considering cosmetic procedures abroad. Patients who develop infections after returning home should promptly seek medical care, and healthcare providers should notify the CDC or appropriate public health authorities when unusual infections or outbreaks are suspected.

Conclusion

Medical tourism may save money but increases serious infection risks. Some cosmetic surgery complications have even resulted in patient deaths. Patients should research clinics and understand risks before traveling.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

Millions around the world still die from preventable diseases every year. Diseases like malaria and tuberculosis remain among the deadliest illnesses globally, especially in poorer regions with limited healthcare access. However, a recent study on malaria vaccine distribution in Africa highlights the life-saving power of preventative medicine when it reaches vulnerable communities. Researchers found that malaria vaccine rollouts in Ghana, Kenya, and Malawi significantly reduced child mortality. Their findings suggest wider vaccine access could save millions of lives within the next decade.

Malaria remains one of the leading causes of child deaths in sub-Saharan Africa. In 2025 alone, roughly 3 million children under age 5 died across the region. Many of these deaths resulted from preventable infectious diseases that are rare in wealthier countries. Globally, child mortality has dropped dramatically over the past three decades. Rates today are less than half of what they were during the 1990s. However, researchers warn that progress may stall or reverse because of cuts to international aid and healthcare funding.

Only two malaria vaccines are currently approved for use worldwide. The first vaccine, called Mosquirix, received approval for rollout in 2015. By 2021, the World Health Organization recommended broader use of the vaccine in regions with high malaria transmission. While the vaccine offers important protection, it is not perfect. Children living in high-risk regions often face several health threats simultaneously, including malnutrition and other infectious diseases. These factors weaken immune systems and increase the likelihood of severe illness or death.

What Are the Findings?

Since 2019, about 1.3 million children in Ghana, Kenya, and Malawi received at least one dose of the Mosquirix vaccine. Researchers designed the vaccine rollout carefully to measure its effectiveness. Roughly half of immunization clinics in selected regions received the vaccine supply, while the remaining clinics continued using mosquito nets and other malaria prevention tools without the vaccine. This allowed researchers to compare child mortality and hospitalization rates between vaccinated and non-vaccinated groups more accurately.

The results were striking. Children in areas with vaccine access showed a 13% reduction in all-cause mortality between 2019 and 2023. In simple terms, vaccine availability prevented roughly 1 in 8 childhood deaths. These findings remained significant even though many children never completed the full four-dose series, partly because of disruptions caused by the COVID-19 pandemic.

Researchers believe the vaccine’s benefits extend beyond malaria prevention alone. In 2024, approximately 440,000 African infants and children died from malaria. However, malaria often combines with other illnesses and weakens the body further, making children more vulnerable to deadly complications. Reducing malaria infections may therefore improve survival across many health conditions simultaneously.

Another important factor may involve increased medical contact. The Mosquirix vaccine requires four doses administered over roughly 18 months. Because children returned repeatedly for vaccinations, healthcare workers had more opportunities to monitor growth, identify illnesses, and provide treatment before conditions became severe. Researchers also found that vaccine clinics reduced child hospitalizations overall, even when malaria infections themselves were not fatal. Additionally, severe malaria infections can impair childhood development and cognitive function, meaning prevention may improve long-term outcomes as well.

What’s Next?

Currently, 25 African countries have introduced malaria vaccines into their healthcare systems. Together, these nations hope to vaccinate roughly 10 million children annually. Some countries facing even higher malaria transmission rates than Ghana, Kenya, and Malawi could potentially see even larger reductions in child mortality. However, healthcare systems in many regions still struggle with funding shortages, political instability, and growing conflicts that make medical access difficult.

Despite these challenges, researchers see reasons for optimism. In May, scientists announced development of a newer malaria vaccine that does not require cold storage transportation. This advancement could dramatically improve vaccine access in remote or underserved communities where refrigeration infrastructure remains limited. Easier transportation and storage may help healthcare workers reach children living far from clinics or hospitals.

Still, questions remain about the newer vaccine’s long-term effectiveness. Researchers do not yet know whether it provides protection lasting as long as Mosquirix. Even so, the success of malaria vaccine programs already demonstrates how preventative medicine can save enormous numbers of lives when resources are available. At a time when global healthcare funding faces growing uncertainty, the study serves as a reminder that access to basic medical tools remains one of the most powerful ways to protect vulnerable children worldwide.

Conclusion

Malaria vaccines in Ghana, Kenya, and Malawi significantly reduced child deaths among young children. Researchers found vaccine access lowered overall mortality by roughly 13% between 2019 and 2023. The findings show that expanding preventative healthcare access could save millions of vulnerable lives worldwide.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of BroneArtUlm.

Sound waves can do more than carry noise through the air. They can shift emotions, sharpen focus, and even help people tolerate discomfort longer during exercise. Now, researchers have discovered another surprising possibility. Ultrasound waves may also destroy dangerous viruses like influenza A H1N1 and SARS-CoV-2, the virus that causes COVID-19.

The research came from scientists at the University of São Paulo in Brazil. Their findings suggest ultrasound could someday become a new antiviral tool. Instead of using chemicals or medications, the treatment physically tears viruses apart using microscopic vibrations.

Viruses like SARS-CoV-2 are surrounded by thin outer membranes. Researchers found that ultrasound waves create vibrations powerful enough to rupture these membranes. Once damaged, the virus spills apart like a leaking water balloon. Without its protective shell, the virus loses much of its ability to infect healthy cells.

What Are the Findings?

The team used ultrasound devices commonly found in hospitals. These machines produced frequencies ranging from 3 to 20 megahertz. Researchers then exposed SARS-CoV-2 samples to the ultrasound blasts and studied the viral particles afterward. Images showed the membranes had clearly ruptured. Viruses hit with ultrasound also struggled to infect laboratory host cells afterward.

Scientists discovered that the treatment works through resonance. Every object has its own natural vibrational frequency, including viral membranes. Ultrasound becomes effective when its vibrations closely match the virus’s natural frequency. The sound waves then amplify those vibrations beyond what the membrane can tolerate. Eventually, the membrane bursts apart under the pressure.

This targeting ability may make ultrasound especially useful medically. Researchers found viral particles were far more vulnerable than surrounding healthy cells. To confirm the results, they carefully monitored nearby cells for heat damage or chemical changes. Measurements showed temperature and pH remained stable during treatment. This helped confirm that sound waves themselves caused the viral destruction.

The shape of viruses also appears important. SARS-CoV-2 and influenza A H1N1 both have mostly spherical shapes. Researchers found spherical viruses absorb ultrasound energy especially well. As energy builds within the membrane, pressure increases until the virus ruptures. Viruses with different shapes may not respond the same way.

Scientists believe this approach could offer several advantages over traditional antivirals. Many medications target specific viral proteins or mutations. Viruses can sometimes evolve resistance against these treatments over time. Ultrasound works differently because it targets physical structure rather than genetic mutations. Researchers think this may give the method longer-lasting effectiveness against evolving viruses.

The team also believes ultrasound could potentially work against other membrane-based viruses. They specifically mentioned dengue, Zika, and chikungunya as possible future targets. Because the method is non-invasive and highly targeted, researchers see broad medical potential if future studies succeed.

Ultrasound already has several medical applications beyond imaging. Researchers continue exploring its use in cancer treatment, pain relief, and neurological therapies. The new findings expand that growing list even further.

Still, researchers caution that much more work remains ahead. Future studies must determine the safest and most effective frequencies for different viruses. Scientists also need to test the treatment in animals and eventually humans before any use becomes possible.

Researchers initially found the results surprising. Ultrasound wavelengths are far larger than viruses themselves. In theory, this size difference should prevent meaningful interaction. However, the virus’s spherical structure appears capable of trapping and concentrating the sound wave energy. In the end, the virus essentially vibrates itself apart. Physics sometimes works in unexpected ways.

Conclusion

Researchers discovered that ultrasound waves can physically rupture viruses like SARS-CoV-2 and influenza. The treatment destroys viral membranes using targeted vibrations without harming nearby healthy cells. Scientists believe this approach could someday provide a non-invasive alternative to antivirals and chemical disinfectants.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Anthony Quintano.

Early hopes around a treatment can change once stronger evidence appears. Sometimes benefits are smaller than first believed. Other times the real value is different than expected.

New research suggests Paxlovid may not lower hospitalization or death rates in certain vaccinated high-risk adults. However, it may still help people recover faster. The findings came from two randomized controlled trials, considered a strong form of medical evidence. Researchers studied people who had received COVID-19 vaccines and were still considered at higher risk for complications.

What Are the Findings?

The trials took place in the United Kingdom and Canada. Together, they included more than 4,000 participants. Most had been vaccinated against COVID-19. Every participant had symptoms for fewer than five days when treatment began. That timing matters because antivirals often work best early in infection.

Participants were randomly assigned into two groups. One group received standard medical care plus Paxlovid. The other group received standard care alone. This design helps researchers compare outcomes fairly and reduce bias.

Patients in the studies were considered high-risk for several reasons. Many were over age 50. Others were younger adults with health conditions linked to worse COVID-19 outcomes. These included illnesses such as Asthma and Diabetes.

The results showed little difference in the most serious outcomes. In one trial, the reduction in hospitalization or death was only 0.1 percent. In the other, the difference was 0.6 percent in favor of Paxlovid. Those numbers suggest the drug did not meaningfully reduce those risks in this specific vaccinated high-risk group.

Yet the medicine still showed possible benefits. In a subgroup of 634 participants, Paxlovid lowered viral load, meaning less virus was detected in the body. That may help explain why recovery improved.

Researchers found Paxlovid increased the odds of early sustained recovery by 36 percent in one trial and 31 percent in the other. In practical terms, some people taking the drug got better sooner and stayed better. For people eager to shorten illness and return to normal life, that may still be meaningful.

Many participants also reported side effects, which is important when weighing treatment choices. Like many medicines, benefits must be balanced against drawbacks.

These findings help clarify Paxlovid’s role in the current stage of the pandemic. For vaccinated high-risk adults, the drug may not strongly cut hospitalization or death risk. But it may still shorten illness, reduce viral burden, and ease recovery. That makes it less of a miracle cure and more of a targeted tool.

Conclusion

Paxlovid did not meaningfully lower hospitalization or death rates in vaccinated high-risk adults in two new trials. It did appear to lower viral load and help some people recover faster. The findings suggest Paxlovid may be more useful for shortening illness than preventing severe outcomes in this group.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

While the COVID-19 pandemic has been declared over, the effects of COVID-19 are still felt across the United States. Fortunately, recent research reinforces the effectiveness of COVID-19 vaccines, showing that the 2025–2026 vaccine reduced emergency room and urgent care visits by 50% and hospitalizations by 55%.

While the virus continues to mutate, this research is crucial. It shows that updated vaccines can still provide meaningful protection against severe illness.

What Were the Covid-19 Vaccine Findings?

The research, published in JAMA Network Open, analyzed nearly 90,000 visits to emergency rooms and urgent care centers. Additionally, researchers reviewed more than 26,000 hospitalizations. These cases included adults aged 18 and older who had symptoms similar to COVID-19.

The study did not include immunocompromised participants. This helped researchers create a clearer baseline for measuring vaccine effectiveness among the general adult population.

To get a comprehensive national view, researchers used a U.S. Centers for Disease Control and Prevention network spanning seven states. This network included more than 250 emergency departments and urgent care centers, as well as nearly 180 hospitals.

While this data aligns with previous research showing vaccine effectiveness, these recent findings also came under scrutiny. The findings were originally slated for CDC publication in April but were later rejected for methodological reasons.

However, the research used a test-negative design, a common method for evaluating vaccine effectiveness. In this approach, researchers include patients who sought medical care for similar symptoms. Then, they compare which patients tested positive for COVID-19 and which had been vaccinated.

This method can help researchers estimate how well vaccines prevent medically attended illness. In this case, the results showed strong protection against both emergency care and hospitalization.

Why Are COVID-19 Vaccines So Important?

Though COVID-19 continues mutating and spreading, a possible summer spike seems to have largely been averted. During summer months, many people spend more time indoors near air conditioning units. As a result, recent years have shown jumps in cases during July and August.

However, COVID-19 caseloads remain substantial. The study estimated around 400,000 to 550,000 infections in the United States between late 2024 and late 2025. In these cases, around 40% of hospitalizations occurred among patients aged 65 and older.

The study also corroborated findings from other recent research published in JAMA Network Open. In that study, COVID-19 vaccination prevented infections severe enough to require medical care by nearly 60% among older adults who had been vaccinated one to two months earlier.

Still, both studies showed low COVID-19 vaccine uptake. In the CDC-linked study, only 11% of patients had received a 2025–2026 booster. In the other study, just 6% of individuals infected with COVID-19 had been vaccinated.

Together, these figures show the continued need for improved trust and higher vaccination rates. While COVID-19 vaccines remain effective, they can only help those who choose to receive them.

For many patients, especially older adults, updated vaccination remains one of the clearest ways to reduce the risk of severe COVID-19.

Conclusion

Recent research shows COVID-19 vaccines still prevent severe illness. Updated boosters reduced emergency visits and hospitalizations among adults. Older adults especially benefit, but vaccination rates remain worryingly low.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.